Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported): March 16, 2010

 

 

COVIDIEN PUBLIC LIMITED COMPANY

(Exact Name of Registrant as Specified in Charter)

 

 

 

Ireland   001-33259   98-0624794

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

Cherrywood Business Park

Block G, First Floor

Loughlinstown, Co. Dublin, Ireland

(Address of Principal Executive Offices, including Zip Code)

+353 (1) 439-3000

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Under the Covidien Severance Plan for U.S. Officers and Executives (the “Executive Severance Plan”), recipients of severance benefits may receive early retirement or normal retirement treatment under restricted stock unit awards and option awards if, during the applicable severance period, they satisfy the age requirement for such treatment (currently age 55 for early retirement and age 60 for normal retirement).

On March 16, 2010, Covidien plc (the “Company”) amended the Executive Severance Plan to extend this treatment to performance share units, effective January 1, 2010. The Executive Severance Plan has also been updated to reflect the Company’s incorporation in Ireland.

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the Company’s Annual General Meeting of Shareholders on March 16, 2010, the shareholders (1) received and considered the Company’s Irish Statutory Accounts and the reports of the Directors and the auditors thereon; (2) elected all eleven of the Company’s nominees for director; (3) appointed Deloitte and Touche LLP to serve as the Company’s independent auditors for the fiscal year ending September 24, 2010 and authorized the Audit Committee to set the auditors’ remuneration; (4) authorized the Company and/or any subsidiary of the Company to make market purchases of the Company’s shares; and (5) passed a special resolution authorizing the reissue price range of treasury shares. Shares were voted on these proposals as follows:

Proposal 1. To receive and consider the Company’s Irish Statutory Accounts for the fiscal year ended September 25, 2009 and the reports of the Directors and the auditors thereon:

 

For

  

Against

  

Abstain

  

Broker Non Vote

401,676,110    343,771    726,114    0


Proposals 2(a)-(k). To re-elect eleven (11) directors to hold office until the Company’s next Annual General Meeting of Shareholders:

 

   

Nominees

   For    Against    Abstain    Broker Non
Vote

(a)

  Craig Arnold    371,838,270    864,985    445,613    29,597,127

(b)

  Robert H. Brust    369,250,057    953,086    2,945,725    29,597,127

(c)

  John M. Connors, Jr.    372,276,475    728,051    144,342    29,597,127

(d)

  Christopher J. Coughlin    371,913,295    789,563    446,010    29,597,127

(e)

  Timothy M. Donahue    371,813,575    887,333    447,960    29,597,127

(f)

  Kathy J. Herbert    372,574,678    435,472    138,718    29,597,127

(g)

  Randall J. Hogan, III    371,829,803    874,868    444,197    29,597,127

(h)

  Richard J. Meelia    275,889,818    10,039,024    87,220,026    29,597,127

(i)

  Dennis H. Reilley    372,274,279    728,511    146,078    29,597,127

(j)

  Tadataka Yamada    372,649,780    356,800    142,288    29,597,127

(k)

  Joseph A. Zaccagnino    372,311,427    693,784    143,657    29,597,127

Proposal 3. Appointment of Deloitte & Touche LLP as the independent auditors of the Company for the fiscal year ending September 24, 2010 and authorization of the Audit Committee to set the auditors’ remuneration:

 

For

  

Against

  

Abstain

  

Broker Non Vote

400,339,786    2,006,037    400,172    0

Proposal 4. To authorize the Company and/or any subsidiary of the Company to make market purchases of Company shares:

 

For

  

Against

  

Abstain

  

Broker Non Vote

400,687,977    384,257    1,673,761    0

Proposal 5. To authorize the reissue price range of treasury shares via special resolution:

 

For

  

Against

  

Abstain

  

Broker Non Vote

379,390,234    21,531,319    1,824,442    0


Item 7.01. Regulation FD Disclosure.

On March 16, 2010, Covidien plc issued a press release announcing that its Board of Directors had authorized a program to purchase up to $1 billion of the Company’s ordinary shares from time to time, based on market conditions.

A copy of the press release is furnished as Exhibit 99.1 to this report.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

99.1   Press Release dated March 16, 2010.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

COVIDIEN PLC
By:  

/S/    JOHN W. KAPPLES        

  John W. Kapples
  Vice President and Corporate Secretary

Date: March 18, 2010


EXHIBIT INDEX

 

Exhibit
No.

 

Exhibit Name

99.1   Press Release dated March 16, 2010.